Synlogic Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023 07:00 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to...
Synlogic Granted Fast Track Designation from FDA for labafenogene marselecobac (SYNB1934) for Treatment of Phenylketonuria
July 11, 2023 07:00 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to...
Synlogic Announces International Nonproprietary Name Selection for SYNB1934
June 28, 2023 07:00 ET
|
Synlogic, Inc.
The World Health Organization has approved “labafenogene marselecobac”Name attributes recognize Synlogic’s proprietary technology and commitment to phenylketonuria communityCAMBRIDGE, Mass., June...
Synlogic Announces Participation in SVB Securities Healthcare Therapeutics Forum
June 27, 2023 07:00 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., June 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to...
Synlogic Reminds Stockholders of 2023 Annual General Meeting Details
June 08, 2023 06:45 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., June 08, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today reminded stockholders that it will...
Synlogic Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria
June 05, 2023 06:45 ET
|
Synlogic, Inc.
Registrational study designed to support BLA submission of first-in-class biotherapeutic Company further streamlining organization to focus resources on execution of late clinical-stage programs in...
Synlogic Announces Appointment of Dr. Dave Hava as Head of Research and Development
January 03, 2023 06:58 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through...
Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU); SYNB1934 Advances to Phase 3
October 18, 2022 06:59 ET
|
Synlogic, Inc.
Positive results include clinically meaningful Phe reductions, with a 60% response rate and 42% reduction in plasma Phe among responders across the study population Consistent, positive measures of...
Synlogic Achieves Research Milestone in Collaboration with Roche for Development of Novel Synthetic Biotic to Treat Inflammatory Bowel Disease
September 06, 2022 07:00 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced today...
Synlogic Granted FDA Fast Track Designation for SYNB1353 for the Treatment of Homocystinuria (HCU)
August 23, 2022 07:00 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...